Physician profile
Adam Rojan
NPI 1285837674
$1,184.06
in general payments reported to CMS, 2019-2025
27 companies · $35.56 in 2025
The $35.56 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281 · 2020: $125 · 2021: $514 · 2022: $101 · 2024: $128 · 2025: $35.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $163.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $163.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $145.96 | 2019-2022 | |
| Intera Oncology, INC | $127.80 | 2024 | Intera |
| Amgen INC. | $122.51 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $94.73 | 2019 | |
| Incyte Corporation | $89.96 | 2019-2022 | |
| Abbvie INC. | $89.76 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.02 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $83.16 | 2019-2022 | |
| Emd Serono, INC. | $45.44 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.29 | 2021 | |
| Celgene Corporation | $34.21 | 2019 | |
| Pfizer INC. | $31.82 | 2021 | |
| Genzyme Corporation | $23.21 | 2021 | |
| Dova Pharmaceuticals | $19.54 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $19.20 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $19.12 | 2020 | |
| Beigene USA, INC. | $16.09 | 2021 | |
| Amag Pharmaceuticals, INC. | $14.98 | 2019 | |
| Taiho Oncology, INC. | $14.83 | 2019 | |
| Foundation Medicine, INC. | $13.89 | 2019 | |
| Deciphera Pharmaceuticals INC. | $13.77 | 2021 | |
| Lilly USA, LLC | $11.75 | 2021 | |
| Janssen Biotech, INC. | $11.57 | 2020 | |
| Seagen INC. | $11.45 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Rojan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.